• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Potential New Treatment For Alcohol Use Disorder Identified By Scientists

December 2, 2022 by Deborah Bloomfield

A medication primarily prescribed for heart problems has shown promise as a treatment for alcohol use disorder (AUD). Combining data from animal experiments with observations in humans, the authors of a new study found that the drug spironolactone reduces drinking in multiple species, with the greatest effects seen in alcohol-dependent individuals.

Inspiration for the study came from previous research that highlighted the role of a hormone called aldosterone in alcoholism. Among people with AUD, higher aldosterone levels have been associated with anxiety, obsessive cravings, alcohol withdrawal, and increased drinking.

Advertisement

Though the mechanism behind this effect is unclear, it’s thought that aldosterone enhances mineralocorticoid receptor signaling, thereby altering the body’s ability to regulate fluid and electrolyte levels. Interestingly, spironolactone is known to block mineralocorticoid receptors, and is administered to counteract the effects of aldosterone and treat fluid build-up following heart failure.

To investigate whether spironolactone also helps to alleviate the symptoms of AUD, the researchers administered the drug to alcohol-dependent mice and rats. A dose-dependent effect was observed in both species, whereby the more spironolactone an animal received, the less they drank.

Experiments in mice also looked at the ability of spironolactone to attenuate binge drinking. Compared to rodents exposed to unsweetened alcohol, those that were given sugary alcoholic drinks tended to gorge themselves, achieving blood alcohol levels that are typically seen following intense drinking sessions.

Advertisement

Encouragingly, spironolactone helped these mice to curtail their boozing but didn’t alter their general food and water intake or decrease their appetite for non-alcoholic sugary drinks.

Turning their attention to humans, the researchers analyzed data from the US Veterans Affairs healthcare system to look for changes in alcohol use amongst those who were prescribed spironolactone for a minimum of 60 continuous days. In total, the study authors compared 10,726 spironolactone-exposed individuals to 34,461 unexposed controls, with highly encouraging results.

Using the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) scale to assess drinking levels, the researchers found that, on average, alcohol intake scores decreased by an extra 0.17 points among those who received the medication. Once again, this effect was found to be dose-dependent, with larger measures of spironolactone correlating with greater decreases in drinking.

Advertisement

Even more importantly, individuals who drank the most at baseline showed the greatest reductions in booze intake. Typically, those who were classed as heavy or hazardous drinkers prior to taking spironolactone achieved a decrease of 0.47 points more than unexposed individuals after treatment.

“Combining findings across three species and different types of research studies, and then seeing similarities in those data, gives us confidence that we are onto something potentially important scientifically and clinically,” explained study author Lorenzo Leggio in a statement. “These findings support further study of spironolactone as a potential treatment for alcohol use disorder, a medical condition that affects millions of people in the US.”

The study has been published in the journal Molecular Psychiatry.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. In 1929 letter, Churchill ponders ‘pleasing and profitable’ pursuits outside politics
  2. China to Wall Street: regulatory crackdown not aimed at restricting private firms
  3. U.S. envoy presses Sudan to move toward civilian rule
  4. Largest Atomic Gas Structure Around Galaxy Group Discovered By Chinese Telescope

Source Link: Potential New Treatment For Alcohol Use Disorder Identified By Scientists

Filed Under: News

Primary Sidebar

  • Did You Know The World’s Largest Waterfall Is Underwater?
  • Video Game Study Found Out What People Do When The World Ends, And It’s Exactly What You’d Expect
  • How Do We Predict The Weather? Find Out More In Issue 40 Of CURIOUS – Out Now
  • You Should Never Leave These Foods In Your Fridge Door (But We Bet You Do)
  • These Gullies On Mars Look Carved – We Might Finally Know What Created Them
  • Potential Environmental Trigger For Autism Identified, 3I/ATLAS’s Tail Appears To Have Changed Direction, And Much More This Week
  • Spaghetti Has Inner Secrets We’re Only Just Learning About
  • How Far Back In Time Could You Go And Still Understand English?
  • We Now Know How The First People Reached America – And It Wasn’t On Foot
  • Two Major Coral Species Now Functionally Extinct In Florida Keys, After Record-Breaking Marine Heatwave
  • A “Super-Earth” In The Habitable Zone Is Half The Distance To Comparable Worlds
  • Adorable But Critically Endangered Bornean Orangutan Born In Conservation Success
  • How Did The FDA Settle On The “2,000 Calories Per Day” Guideline?
  • Comet 3I/ATLAS Losing At Least Two Kangaroos’ Worth Of Dust Every Second
  • Mummified Dinosaur Duo Prove They Had Hooves, Marking “The First Confirmed Hooved Reptile”
  • What Do The Numbers On Your Toaster Really Mean?
  • NASA Vs. Elon Musk: Is A Moon Landing This Decade Off The Cards?
  • Scientists Explored Some Of The Deepest Parts Of The Ocean And Spotted Some Seriously Weird Deep-Sea Creatures
  • 500-Meter-Tall Megatsunami Struck Remote Alaskan Fjord After Massive Landslide
  • 3I/ATLAS, CKM Syndrome, And Mosquitoes’ Final Frontier
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version